Loretta M. Itri

16.9k total citations · 9 hit papers
91 papers, 10.9k citations indexed

About

Loretta M. Itri is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Loretta M. Itri has authored 91 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 24 papers in Molecular Biology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Loretta M. Itri's work include Cancer Treatment and Pharmacology (15 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (10 papers). Loretta M. Itri is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (10 papers). Loretta M. Itri collaborates with scholars based in United States, France and Germany. Loretta M. Itri's co-authors include JE Groopman, Russell K. Portenoy, Pietro Ghezzi, Michael Brines, Anthony Cerami, Jerome E. Groopman, Davide Agnello, Nihal C. de Lanerolle, Gregory A. Curt and Sandra J. Horning and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Loretta M. Itri

89 papers receiving 10.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury

2000 1.2k citations Loretta M. Itri et al. profile →
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck

1990 1.1k citations S. M. Lippman, Loretta M. Itri et al. profile →
Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

1991 1.1k citations Loretta M. Itri et al. profile →
Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

2000 979 citations Jerome E. Groopman, Loretta M. Itri et al. profile →
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment

1999 738 citations Loretta M. Itri et al. JNCI Journal of the National Cancer Institute profile →
13-cis-Retinoic Acid in the Treatment of Oral Leukoplakia

1986 633 citations Loretta M. Itri, Richard H. Bell et al. profile →
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.

1997 625 citations Jerome E. Groopman, Loretta M. Itri et al. profile →
Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting

1981 555 citations Richard J. Gralla, Loretta M. Itri et al. profile →
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Loretta M. Itri

Since Specialization

Citations

This map shows the geographic impact of Loretta M. Itri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loretta M. Itri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loretta M. Itri more than expected).

Fields of papers citing papers by Loretta M. Itri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loretta M. Itri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loretta M. Itri. The network helps show where Loretta M. Itri may publish in the future.

Co-authorship network of co-authors of Loretta M. Itri

This figure shows the co-authorship network connecting the top 25 collaborators of Loretta M. Itri. A scholar is included among the top collaborators of Loretta M. Itri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loretta M. Itri. Loretta M. Itri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300) 2023 ·Gynecologic Oncology ·Elizabeth Lee, Jordi Rodón, Michael J. Demeure, Dustin A. Deming, Noah Federman, Meredith McKean, Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David K. Crockett, Kristen N. Ganjoo, (unknown), Lee D. Cranmer, Anita Schmid, Willis H. Navarro, Loretta M. Itri, Gopa Iyer	1
2	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). 2023 ·Journal of Clinical Oncology ·Gopa Iyer, Michael J. Demeure, Dustin A. Deming, Noah Federman, Meredith McKean, (unknown), Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David G. Crockett, Kristen N. Ganjoo, (unknown), (unknown), Anita N. Schmid, Willis H. Navarro, Loretta M. Itri	0
3	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I). 2023 ·Journal of Clinical Oncology ·Dustin A. Deming, Jordi Rodón, Michael J. Demeure, Noah Federman, Meredith McKean, (unknown), Alexander I. Spira, David J. Kwiatkowski, Maen Hussein, Erlinda M. Gordon, David G. Crockett, Kristen N. Ganjoo, (unknown), (unknown), Anita N. Schmid, Willis H. Navarro, Loretta M. Itri, Gopa Iyer	1
4	Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer 2022 ·npj Breast Cancer ·Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky	68
5	LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI) 2020 ·Annals of Oncology ·Yohann Loriot, Arjun Vasant Balar, Daniel P. Petrylak, Scott T. Tagawa, Arash Rezazadeh, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Q. Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas	19
6	LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) 2020 ·Annals of Oncology ·Aditya Bardia, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Lisa A. Carey, (unknown), Martine Piccart, Sibylle Loibl, D M Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz	51
7	Fentanyl Iontophoretic Transdermal System (IONSYS®) can be Safely used in the Hospital Environment with X-Rays, Computerized Tomography and Radiofrequency Identification Devices 2016 ·Advances in Therapy ·(unknown), (unknown), J. Bradley Phipps, Niki Patel, Loretta M. Itri, James F. Caravelli, Eugene R. Viscusi	3
8	High Body Mass Index and Use of Fentanyl Iontophoretic Transdermal System in Postoperative Pain Management: Results of a Pooled Analysis of Six Phase 3/3B Trials 2016 ·Pain and Therapy ·Eugene R. Viscusi, Li Ding, J. Bradley Phipps, Loretta M. Itri, Philip R. Schauer	3
9	LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951) 2009 ·European Journal of Cancer ·Sanjiv S. Agarwala, Ulrich Keilholz, (unknown), Agop Y. Bedikian, Jane Wu, Richard Kay, Cy A. Stein, Loretta M. Itri, Stefan Suciu, Alexander M.M. Eggermont	106
10	B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Roy S. Herbst, Rafat Ansari, В. А. Горбунова, Georgy M. Manikhas, Mansoor N. Saleh, Thomas E. Boyd, Christopher G. Azzoli, Francisco Robert, Loretta M. Itri, Robert Chapman	2
11	Managing cancer‐related anaemia with epoetin alfa 2002 ·Nephrology Dialysis Transplantation ·Loretta M. Itri	6
12	Cancer chemoprevention 1993 ·Cancer ·Loretta M. Itri	213
13	13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin 1992 ·JNCI Journal of the National Cancer Institute ·S. M. Lippman, David Parkinson, Loretta M. Itri, Randal S. Weber, Stimson P. Schantz, David M. Ota, Mark A. Schusterman, I. H. Krakoff, Jordan U. Gutterman, W. K. Hong	305
14	Interferon-??2a in the Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi??s Sarcoma 1991 ·Journal of Immunotherapy ·Lydia M. Evans, Loretta M. Itri, Marilyn Campion, (unknown), Susan E. Krown, Jerome E. Groopman, Howard Goldsweig, Paul A. Volberding, Susan West, Ronald T. Mitsuyasu, Zofia E. Dziewanowska	47
15	Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. 1989 ·Journal of Clinical Oncology ·Scott Wadler, Edward L. Schwartz, Marc Goldman, (unknown), Michael Rader, Matthew Zimmerman, Loretta M. Itri, V. Weinberg, P H Wiernik	271
16	The use of cis-retinoic acid in recurrent respiratory papillomatosis of the larynx: A randomized pilot study 1988 ·American Journal of Otolaryngology ·Richard H. Bell, (unknown), Loretta M. Itri, (unknown), M. Stuart Strong	34
17	Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. 1988 ·Journal of Clinical Oncology ·Figlin Ra, (unknown), Eliahu Mukamel, Alicia V. Palleroni, Loretta M. Itri, Gregory Sarna	52
18	Vindesine with cisplatin in non-small lung cancer (NSCLC): The influence on survival and the effect of adding conventional agents 1981 ·Proceedings of the American Association for Cancer Research ·Loretta M. Itri, Richard J. Gralla, E. S. Casper	1
19	VP-16-213: A phase II study of non-small cell lung cancer (NSCLC) 1981 ·Proceedings of the American Association for Cancer Research ·Loretta M. Itri, Richard J. Gralla, David P. Kelsen	2
20	High dose metoclopramide: Effective antiemetic against cisplatin (DDP) in randomized trials VS. placebo and prochlorperazine (PCP) 1981 ·Proceedings of the American Association for Cancer Research ·Richard J. Gralla, (unknown), Loretta M. Itri	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact